A Resectable Tumor, and the Argument for Treating It Before Surgery Anyway
A single patient with a technically resectable, EGFR-mutant lung cancer. The disagreement isn't whether he needs osimertinib — it's whether giving it before an operation that was never in question buys anything the proven adjuvant approach doesn't already deliver afterward.
T.K., 64, coached football at the same high school for 28 years before retiring, and still shows up most Friday nights in the fall “because I can't stay away.” A pre-retirement physical six weeks ago caught an incidental 3.8cm right upper lobe mass on a screening low-dose CT he almost skipped; biopsy confirmed adenocarcinoma with an EGFR exon 19 deletion, staging complete with a single involved N1 node and no distant spread — stage IIB. Thoracic surgery's own review of his imaging describes the mass as abutting, not invading, a segmental pulmonary artery branch: technically resectable with a standard lobectomy, not a borderline case that would need shrinking first to become operable at all.
That distinction rules out one argument and only one. Converting an impossible operation into a possible one is the rationale that plainly does not apply to him — by the surgical team's own assessment, his operation was never impossible. It is not, however, the only rationale on offer. What is well established is what happens after a resection like his: ADAURA found a substantial disease-free and overall survival benefit from three years of adjuvant osimertinib in resected, EGFR-mutant, stage IB–IIIA disease — his own stage and mutation, studied at real scale, with a real survival endpoint already reported. His only real comorbidity, well-controlled hypertension on a single agent, is not going to decide anything here; he can tolerate what's coming in either order. NeoADAURA, testing that other order, enrolled stage II–IIIB N2 disease and met its primary endpoint of major pathologic response. He sits inside that population too. So both trials describe him, and the room is not choosing between an evidence-based option and a speculative one — it is choosing which of two endpoints to be governed by, a survival benefit already reported, or a pathologic response whose relationship to survival in EGFR-driven disease is still unestablished.
Before the operation, or after it
Proceed straight to lobectomy, then start adjuvant osimertinib. ADAURA established a substantial disease-free and overall survival benefit from exactly that sequence in resected, EGFR-mutant, stage IB to IIIA disease — his stage sits inside that, and overall survival is the endpoint it actually reported.
NeoADAURA isn't emerging data anymore — it's a randomized phase III in stage II to IIIB N2 resectable EGFR-mutant disease, 358 patients, and it met its primary endpoint: significantly higher major pathologic response with neoadjuvant osimertinib, with or without chemotherapy, than with chemotherapy alone. He's stage IIB with an N1 node, which puts him inside that trial too. Addressing micrometastatic disease before surgical manipulation could plausibly reduce tumor-cell seeding at resection, an advantage adjuvant-only dosing can't offer by definition.
You're right that ADAURA's evidence is the strongest thing either of us can point to today — but it only tells us adjuvant osimertinib helps after surgery. It says nothing about whether starting earlier helps more, because that's not the comparison ADAURA ever made.
I'll grant the point I can't argue with: NeoADAURA enrolled resectable patients, so I can't dismiss it by saying downstaging is the only reason to treat first — it isn't, and that trial's whole design says so. What I can say is what its endpoint is. Major pathologic response is a tissue finding at the time of my operation. It is not survival, it has never been validated as a surrogate for survival in EGFR-driven disease, and NeoADAURA's own event-free survival data are immature. ADAURA reported overall survival. So the honest comparison isn't proven-versus-theoretical, it's a reported survival benefit against a pathologic endpoint that may or may not turn into one. On a tumor that abuts rather than invades and comes out cleanly next week, I'd take the survival number.
Agreed: proceed to lobectomy as planned; initiate adjuvant osimertinib per the established post-operative protocol.
Not agreed: whether a future, genuinely borderline-resectable case at this center should default toward neoadjuvant trial enrollment. The second oncologist wants a standing referral pathway for such patients; the surgeon prefers case-by-case operability assessment without a default rule.